These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 22351718)
1. Hepatitis C: the end of the beginning and possibly the beginning of the end. Alter HJ; Liang TJ Ann Intern Med; 2012 Feb; 156(4):317-8. PubMed ID: 22351718 [No Abstract] [Full Text] [Related]
2. The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings. Vuppalanchi R; Kwo PY Gastroenterology; 2013 Feb; 144(2):457-459. PubMed ID: 23260498 [No Abstract] [Full Text] [Related]
4. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Liu S; Cipriano LE; Holodniy M; Owens DK; Goldhaber-Fiebert JD Ann Intern Med; 2012 Feb; 156(4):279-90. PubMed ID: 22351713 [TBL] [Abstract][Full Text] [Related]
5. Antiviral agents and hepatitis C. Archer-Festa M; Nilsen-Kupsch S N Y State Dent J; 2012; 78(4):42-5. PubMed ID: 23252194 [TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542 [TBL] [Abstract][Full Text] [Related]
7. Special report: cost-effectiveness studies of new hepatitis C treatments. Mark DH; Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188 [No Abstract] [Full Text] [Related]
8. Infectious diseases. First specific drugs raise hopes for hepatitis C. Enserink M Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720 [No Abstract] [Full Text] [Related]
9. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments. Cobb B; Vilchez RA Hepatology; 2012 Mar; 55(3):979-80; author reply 980-1. PubMed ID: 22161994 [No Abstract] [Full Text] [Related]
10. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Eckman MH; Ward JW; Sherman KE Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597 [TBL] [Abstract][Full Text] [Related]
11. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. Waked I; Esmat G; Elsharkawy A; El-Serafy M; Abdel-Razek W; Ghalab R; Elshishiney G; Salah A; Abdel Megid S; Kabil K; El-Sayed MH; Dabbous H; El Shazly Y; Abo Sliman M; Abou Hashem K; Abdel Gawad S; El Nahas N; El Sobky A; El Sonbaty S; El Tabakh H; Emad E; Gemeah H; Hashem A; Hassany M; Hefnawy N; Hemida AN; Khadary A; Labib K; Mahmoud F; Mamoun S; Marei T; Mekky S; Meshref A; Othman A; Ragab O; Ramadan E; Rehan A; Saad T; Saeed R; Sharshar M; Shawky H; Shawky M; Shehata W; Soror H; Taha M; Talha M; Tealaab A; Zein M; Hashish A; Cordie A; Omar Y; Kamal E; Ammar I; AbdAlla M; El Akel W; Doss W; Zaid H N Engl J Med; 2020 Mar; 382(12):1166-1174. PubMed ID: 32187475 [No Abstract] [Full Text] [Related]
12. Protease inhibitors in hepatitis C: from chronic disease to cure. Iqbal M; McCormick PA Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874 [No Abstract] [Full Text] [Related]
13. Data to guide the "test and treat era" of hepatitis C. Ward JW; Rein DB; Smith BD Gastroenterology; 2012 Oct; 143(4):887-9. PubMed ID: 22922026 [No Abstract] [Full Text] [Related]
14. Rapid virological response: is it four or eight weeks? Milazzo L; Foschi A; Antinori S Hepatology; 2012 Mar; 55(3):979; author reply 980-1. PubMed ID: 22161760 [No Abstract] [Full Text] [Related]
15. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S; J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144 [TBL] [Abstract][Full Text] [Related]
16. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. Langness JA; Tabano D; Wieland A; Tise S; Pratt L; Harrington LA; Lin S; Ghuschcyan V; Nair KV; Everson GT Ann Hepatol; 2017; 16(3):366-374. PubMed ID: 28425406 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. McEwan P; Bennett H; Ward T; Webster S; Gordon J; Kalsekar A; Yuan Y; Brenner M Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):173-80. PubMed ID: 26545086 [TBL] [Abstract][Full Text] [Related]
18. Viral hepatitis C in 2014--the beginning of the end? Prelipcean CC; Gogălniceanu P; Mihai C Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):272-8. PubMed ID: 25076687 [No Abstract] [Full Text] [Related]
19. Protease inhibitors for hepatitis C: economic implications. Turner SJ; Brown J; Paladino JA Pharmacoeconomics; 2013 Sep; 31(9):739-51. PubMed ID: 23839698 [TBL] [Abstract][Full Text] [Related]
20. [Hepatitis C therapy: a problem almost solved]. Rizzetto M Recenti Prog Med; 2014 Jun; 105(6):225-6. PubMed ID: 25002283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]